After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.
Novartis’ Intrathecal Zolgensma Effective in Older Children Read More »
Mary Jo Cagle’s last day at Cone Health is May 31. The health system has not yet named her permanent successor.
The Philadelphia-area system and a major insurer have failed to reach a new agreement on payment rates, but are still continuing negotiations.
En un mundo donde la información se ha convertido en un activo estratégico, proteger los datos empresariales es fundamental. Las organizaciones enfrentan riesgos constantes asociados a ciberataques, accesos no autorizados y filtraciones de información sensible. …
Tácticas para fortalecer la seguridad de la información en las empresas Read More »
Nostalgia y búsqueda de contacto con actualidad por parte de los españoles residentes en otros países. Afinidad de personas cuyos familiares están en España y buscan cómo contextualizar sus conversaciones. Observar la calidad de ayer y hoy, por sie …
Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to focus on another next-gen asset for the indication.
Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another Read More »
The massive pharmacy benefit manager plans to stop requiring coverage reauthorizations for roughly 80 drugs used to treat migraines, multiple sclerosis, high cholesterol and more.
Optum Rx says it will eliminate 10% of prior authorizations Read More »
Monogram Technologies secured 510(k) clearance for its robotic knee replacement system, while Vicarious Surgical blamed supply chain issues for delaying its regulatory timeline.
Monogram robot wins FDA OK; Vicarious hit by supplier woes Read More »
Medtronic will remove one model of Pipeline Vantage devices from where they’re used and sold and will update the instructions for another model.
Medtronic recalls embolization devices tied to 17 injuries, 4 deaths Read More »
The French pharma is getting Black Diamond’s de-prioritized molecule for non-small cell lung cancers with specific mutations whose development had been paused to save money.
Servier Nabs Solid Tumor Asset in up to $780M Deal With Black Diamond Read More »
